Landmann R, Fisscher A E, Obrecht J P
Department of Research, University Hospital, Basel, Switzerland.
J Leukoc Biol. 1992 Sep;52(3):323-30. doi: 10.1002/jlb.52.3.323.
CD14 is a 53-kd glycoprotein that is mainly expressed in myeloid cells and exists in two forms. The membrane-bound form represents the receptor for complexes of lipopolysaccharide (LPS) with LPS binding protein. The function and regulation of the soluble form are unknown. In the present study we investigated the release of soluble CD14 (sCD14) in cultures of human mononuclear leukocytes, elutriated monocytes, and monocyte-derived macrophages. The release of sCD14 into the medium of the cells cultured for 15 and 45 h was investigated in the absence or presence of selected cytokines. sCD14 release occurred constitutively and correlated with cell number. In monocytes differentiating into macrophages, cumulative release of sCD14 was linear from day 1 to day 7. Spontaneous sCD14 release after 15 h of culture (2 x 10(6) cells/ml) was higher in the supernatant from monocytes (314 +/- 58 ng/ml) than that from mononuclear leukocytes (68 +/- 10 ng/ml) and similar to that from macrophages (469 +/- 79 ng/ml). Cycloheximide and actinomycin D inhibited sCD14 release. Recombinant interferon-gamma (rIFN-gamma) and recombinant interleukin-4 (rIL-4) directly decreased sCD14 release in mononuclear leukocyte, monocyte, and macrophage cultures. rIL-2 and rIFN-alpha reduced sCD14 release into the supernatants of mononuclear leukocytes only. Use of anti-IFN-gamma antibodies indicated that the down-regulation of sCD14 release by rIL-2 and rIFN-alpha was partially due to induction of endogenous IFN-gamma. The down-regulation of sCD14 release by all four cytokines was both time and dose dependent. rIFN-gamma and rIL-4 added simultaneously had a synergistic effect on sCD14 down-regulation. In conclusion, sCD14 release may have an immunomodulatory role in circulating monocytes, is apparently not related to the process of macrophage differentiation, and is selectively down-regulated during an immune response when levels of IFN-gamma and IL-4 are high.
CD14是一种53千道尔顿的糖蛋白,主要在髓细胞中表达,以两种形式存在。膜结合形式代表脂多糖(LPS)与LPS结合蛋白复合物的受体。可溶性形式的功能和调节尚不清楚。在本研究中,我们调查了人单核白细胞、淘洗单核细胞和单核细胞衍生巨噬细胞培养物中可溶性CD14(sCD14)的释放情况。在有或没有选定细胞因子存在的情况下,研究了培养15小时和45小时的细胞培养基中sCD14的释放。sCD14的释放是组成性的,且与细胞数量相关。在分化为巨噬细胞的单核细胞中,从第1天到第7天,sCD14的累积释放呈线性。培养15小时(2×10⁶细胞/毫升)后,单核细胞上清液中的自发sCD14释放量(314±58纳克/毫升)高于单核白细胞(68±10纳克/毫升),与巨噬细胞(469±79纳克/毫升)相似。放线菌酮和放线菌素D抑制sCD14的释放。重组干扰素-γ(rIFN-γ)和重组白细胞介素-4(rIL-4)直接降低单核白细胞、单核细胞和巨噬细胞培养物中sCD14的释放。rIL-2和rIFN-α仅减少单核白细胞上清液中sCD14的释放。使用抗IFN-γ抗体表明,rIL-2和rIFN-α对sCD14释放的下调部分归因于内源性IFN-γ的诱导。所有四种细胞因子对sCD14释放的下调均呈时间和剂量依赖性。同时添加rIFN-γ和rIL-4对sCD14下调具有协同作用。总之,sCD14的释放可能在循环单核细胞中具有免疫调节作用,显然与巨噬细胞分化过程无关,并且在免疫反应期间,当IFN-γ和IL-4水平较高时被选择性下调。